While Merck's underlying business growth is positioning the company favorably for the future, and the R&D focus on PD-1 and hepatitis C treatments suggests great positive potential long-term, short-term reactions might remains cautious. Key concerns include:a persistent pressure on gross margins, continued cost management, and ongoing pricing pressures in the diabetes market. The impending exit from the AstraZeneca JV in 2014 may introduce a period of uncertainty. 

**Reasoning**: Despite some operational adjustments and optimism around their pipeline, near-term performance indicators and external market dynamics may temper investor enthusiasm within the 1â€“2 week window.

**Rating**

[0]